Trial intelligence / Profile preview

Ketorolac vs Ibuprofen for Acute Musculoskeletal Pain

NCT05239767Phase 4

Key facts

Status: Completed
Start: Jun 2022
Primary completion: Apr 2023
Countries: 1
Sponsor: Montefiore Medical Center
Modality: Small Molecules

Drugs: ketorolacibuprofen
Conditions: Musculoskeletal painacute pain

Overview

Phase 4, randomised, triple-blind trial in Musculoskeletal pain and acute pain comparing Ketorolac with Ibuprofen (2 arms). Primary endpoint: Failure to achieve a minimum clinically important difference at 2 hours. Started Jun 2022; status: completed.

Design

2 arms

Study design: RandomizedTriple-blind

Ketorolac
Ketorolac 20mg orally x 1
Ibuprofen
Ibuprofen 800mg orally x 1

Who it enrols

Adults with acute moderate-to-severe musculoskeletal pain (duration <= 10 days) without chronic pain in the same region, excluding those with contraindications to NSAIDs or acetaminophen or recent use of these medications.

Endpoints

Primary

Failure to achieve a minimum clinically important difference2 hours

Secondary

0-10 pain score2 hours
Ordinal pain scale2 hours
Epigastric pain2 hours

Beyond the preview

Go deeper on NCT05239767.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05239767.